Analysts’ New Coverage for June 2nd (GH, GRAL, MANE, MIRM, MOBI, MTD, NBIS, NBIX, NTRA, NUTX)

Analysts’ new coverage for Tuesday, June 2nd:

Wolfe Research assumed coverage on shares of Guardant Health (NASDAQ:GH). The firm issued an outperform rating and a $150.00 price target on the stock.

Wolfe Research assumed coverage on shares of GRAIL (NASDAQ:GRAL). The firm issued a peer perform rating on the stock.

Needham & Company LLC assumed coverage on shares of Veradermics (NYSE:MANE). Needham & Company LLC issued a buy rating and a $136.00 target price on the stock.

Citigroup Inc. initiated coverage on shares of Mirum Pharmaceuticals (NASDAQ:MIRM). They issued a buy rating and a $145.00 price target on the stock.

JPMorgan Chase & Co. initiated coverage on shares of Mobia Medical (NASDAQ:MOBI). JPMorgan Chase & Co. issued an overweight rating and a $15.00 target price on the stock.

Bank of America Corporation initiated coverage on shares of Mobia Medical (NASDAQ:MOBI). They issued a buy rating and a $16.00 price target on the stock.

BTIG Research initiated coverage on shares of Mobia Medical (NASDAQ:MOBI). They issued a buy rating and a $19.00 target price on the stock.

Wolfe Research assumed coverage on shares of Mettler-Toledo International (NYSE:MTD). The firm issued a peer perform rating on the stock.

BNP Paribas Exane began coverage on shares of Nebius Group (NASDAQ:NBIS). They issued a neutral rating and a $255.00 price target on the stock.

The Goldman Sachs Group, Inc. began coverage on shares of Neurocrine Biosciences (NASDAQ:NBIX). They issued a buy rating and a $213.00 price target on the stock.

Wolfe Research began coverage on shares of Natera (NASDAQ:NTRA). They issued an outperform rating and a $260.00 price target on the stock.

Lake Street Capital began coverage on shares of Nutex Health (NASDAQ:NUTX). Lake Street Capital issued a buy rating and a $235.00 target price on the stock.

Wedbush started coverage on shares of Odyssey Therapeutics (NASDAQ:ODTX). The firm issued an outperform rating and a $30.00 target price on the stock.

JPMorgan Chase & Co. initiated coverage on shares of Odyssey Therapeutics (NASDAQ:ODTX). They issued an overweight rating and a $26.00 price target on the stock.

Oppenheimer Holdings, Inc. initiated coverage on shares of Odyssey Therapeutics (NASDAQ:ODTX). Oppenheimer Holdings, Inc. issued an outperform rating and a $40.00 target price on the stock.

Wolfe Research began coverage on shares of Repligen (NASDAQ:RGEN). The firm issued an outperform rating and a $145.00 price target on the stock.

Wolfe Research began coverage on shares of Revvity (NYSE:RVTY). They issued a peer perform rating on the stock.

Wolfe Research initiated coverage on shares of Stevanato Group (NYSE:STVN). Wolfe Research issued an outperform rating and a $21.00 target price on the stock.

Wolfe Research initiated coverage on shares of Tempus AI (NASDAQ:TEM). The firm issued a peer perform rating on the stock.

Wolfe Research assumed coverage on shares of Thermo Fisher Scientific (NYSE:TMO). They issued an outperform rating and a $535.00 price target on the stock.

Piper Sandler began coverage on shares of Take-Two Interactive Software (NASDAQ:TTWO). Piper Sandler issued an overweight rating and a $280.00 price target on the stock.

Piper Sandler assumed coverage on shares of Unity Software (NYSE:U). The firm issued an overweight rating and a $40.00 price target on the stock.

The Goldman Sachs Group, Inc. started coverage on shares of Victory Capital (NASDAQ:VCTR). The Goldman Sachs Group, Inc. issued a neutral rating and a $90.00 price target on the stock.

Wolfe Research initiated coverage on shares of Veracyte (NASDAQ:VCYT). The firm issued an outperform rating and a $55.00 target price on the stock.

Wolfe Research initiated coverage on shares of Waters (NYSE:WAT). They issued an outperform rating and a $425.00 price target on the stock.

Leerink Partners initiated coverage on shares of X4 Pharmaceuticals (NASDAQ:XFOR). The firm issued an outperform rating and a $12.00 price target on the stock.